PriceTargets.com logo

Bausch Health Companies - BHC Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $7.75
  • Forecasted Upside: 3.75%
  • Number of Analysts: 7
  • Breakdown:
  • 1 Sell Ratings
  • 5 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$7.47 As of 12/20/2024 06:31 PM ET
▲ +0.08 (1.08%)

This chart shows the closing price for BHC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Bausch Health Companies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BHC

Analyst Price Target is $7.75
▲ +3.75% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Bausch Health Companies in the last 3 months. The average price target is $7.75, with a high forecast of $11.00 and a low forecast of $3.00. The average price target represents a 3.75% upside from the last price of $7.47.

This chart shows the closing price for BHC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 7 contributing investment analysts is to hold stock in Bausch Health Companies. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
6/30/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/28/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
12/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/24/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
9/22/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
11/21/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
12/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/1/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$10.00 ➝ $11.00
10/15/2024Evercore ISIUpgradeHold
8/7/2024Jefferies Financial GroupLower TargetBuy$13.00 ➝ $9.00
8/2/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$10.00 ➝ $8.50
8/2/2024ScotiabankLower TargetSector Perform$10.00 ➝ $8.50
8/2/2024Piper SandlerDowngradeNeutral ➝ Underweight$9.00 ➝ $3.00
7/25/2024Truist FinancialLower TargetHold ➝ Hold$8.00 ➝ $7.00
7/10/2024Raymond JamesInitiated CoverageMarket Perform$8.00
4/29/2024Piper SandlerBoost TargetNeutral$7.00 ➝ $9.00
4/23/2024Royal Bank of CanadaLower TargetSector Perform ➝ Sector Perform$12.00 ➝ $11.00
4/12/2024Royal Bank of CanadaReiterated RatingSector Perform ➝ Sector Perform$12.00
4/5/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$9.00 ➝ $12.00
2/23/2024Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$8.00 ➝ $9.00
2/20/2024Jefferies Financial GroupLower TargetBuy$16.00 ➝ $14.00
9/20/2023Jefferies Financial GroupUpgradeHold ➝ Buy$9.00 ➝ $16.00
7/24/2023Royal Bank of CanadaBoost TargetSector Perform$8.00 ➝ $9.00
6/16/2023TD CowenDowngradeOutperform ➝ Market Perform
5/22/2023Jefferies Financial GroupBoost Target$7.00 ➝ $9.50
9/9/2022Piper SandlerLower TargetNeutral$7.00 ➝ $6.00
9/1/2022Royal Bank of CanadaBoost TargetSector Perform$4.50 ➝ $8.00
8/10/2022Royal Bank of CanadaLower TargetSector Perform$5.00 ➝ $4.50
7/29/2022Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$12.00 ➝ $5.00
7/28/2022Truist FinancialDowngradeBuy ➝ Hold
7/28/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral
6/13/2022JPMorgan Chase & Co.Initiated CoverageOverweight$12.00
5/26/2022Piper SandlerLower Target$27.00 ➝ $7.00
5/15/2022Royal Bank of CanadaLower TargetOutperform$21.00 ➝ $17.00
5/11/2022BMO Capital MarketsLower Target$26.00 ➝ $15.00
5/11/2022Bank of AmericaLower Target$25.00 ➝ $12.00
5/9/2022Royal Bank of CanadaLower TargetOutperform$32.00 ➝ $21.00
2/1/2022Royal Bank of CanadaLower TargetOutperform$40.00 ➝ $34.00
11/8/2021BMO Capital MarketsReiterated RatingHold
11/3/2021Royal Bank of CanadaLower TargetOutperform$41.00 ➝ $40.00
10/1/2021Jefferies Financial GroupReiterated RatingBuy
8/4/2021BarclaysLower TargetIn-Line ➝ Overweight$35.00 ➝ $31.00
7/8/2021HC WainwrightReiterated RatingBuy
5/5/2021Royal Bank of CanadaLower TargetOutperform$42.00 ➝ $41.00
3/30/2021Bank of AmericaReiterated RatingNeutral ➝ Underperform$27.00
3/24/2021Bank of AmericaDowngradeNeutral ➝ Underperform$27.00
3/16/2021HC WainwrightBoost TargetBuy$50.00 ➝ $55.00
3/14/2021JPMorgan Chase & Co.Reiterated RatingBuy$38.00
3/2/2021CitigroupBoost Target$32.00 ➝ $37.00
2/26/2021Morgan StanleyBoost TargetEqual Weight$22.00 ➝ $35.00
2/25/2021BarclaysBoost TargetOverweight$27.00 ➝ $35.00
2/17/2021Royal Bank of CanadaUpgradeSector Perform ➝ Outperform$26.00 ➝ $42.00
2/16/2021JPMorgan Chase & Co.Boost TargetOverweight$32.00 ➝ $38.00
1/22/2021Piper SandlerDowngradeOverweight ➝ Neutral$25.00 ➝ $30.00
1/15/2021Jefferies Financial GroupBoost Target$27.00 ➝ $33.00
11/5/2020Piper SandlerLower TargetOverweight$26.00 ➝ $25.00
10/28/2020Wells Fargo & CompanyLower TargetEqual Weight$18.00 ➝ $17.00
10/26/2020BarclaysBoost TargetOverweight$28.00 ➝ $29.00
9/17/2020Bank of AmericaUpgradeUnderperform ➝ Neutral$19.00
8/24/2020HC WainwrightReiterated RatingBuy$64.00 ➝ $50.00
8/19/2020Piper SandlerLower TargetOverweight$32.00 ➝ $26.00
8/10/2020Royal Bank of CanadaBoost TargetSector Perform$23.00 ➝ $26.00
8/10/2020CitigroupLower TargetBuy$27.00 ➝ $26.00
8/7/2020BarclaysBoost TargetOverweight$25.00 ➝ $28.00
7/31/2020Royal Bank of CanadaLower TargetSector Perform$24.00 ➝ $23.00
7/7/2020Bank of AmericaBoost TargetUnderperform$12.00 ➝ $14.00
6/17/2020HC WainwrightBoost TargetBuy$50.00 ➝ $64.00
5/8/2020CfraLower TargetHold$28.00 ➝ $18.00
5/8/2020SunTrust BanksLower TargetBuy$25.00 ➝ $24.00
5/8/2020Royal Bank of CanadaLower TargetSector Perform$25.00 ➝ $24.00
4/30/2020Wells Fargo & CompanyBoost TargetEqual Weight$17.00 ➝ $18.00
4/28/2020HC WainwrightReiterated RatingBuy$50.00
4/28/2020Royal Bank of CanadaLower TargetSector Perform$26.00 ➝ $25.00
4/24/2020CitigroupInitiated CoverageBuy$30.00
4/23/2020Jefferies Financial GroupLower TargetBuy$35.00 ➝ $27.00
4/2/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight
3/23/2020HC WainwrightLower TargetBuy$60.00 ➝ $50.00
3/23/2020Wells Fargo & CompanyLower TargetEqual Weight$32.00 ➝ $17.00
3/17/2020Royal Bank of CanadaLower TargetSector Perform$31.00 ➝ $26.00
2/20/2020Royal Bank of CanadaLower TargetSector Perform$33.00 ➝ $31.00
2/20/2020SunTrust BanksLower TargetBuy$32.00 ➝ $31.00
2/19/2020CowenReiterated RatingBuy$40.00
2/19/2020GuggenheimReiterated RatingBuy$36.00
2/11/2020Morgan StanleyLower TargetOverweight$34.00 ➝ $32.00
2/4/2020Royal Bank of CanadaBoost TargetSector Perform$31.00 ➝ $33.00
1/29/2020Wolfe ResearchDowngradeOutperform ➝ Peer Perform
1/26/2020BarclaysReiterated RatingBuy$33.00
1/22/2020Wells Fargo & CompanyUpgradeUnderweight ➝ Equal Weight$32.00
12/30/2019Piper Sandler CompaniesBoost TargetNeutral ➝ Overweight$30.00 ➝ $39.00
12/23/2019HC WainwrightReiterated RatingBuy$60.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.09 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 6 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 10 very positive mentions
  • 14 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 11 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 8 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 5 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 17 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 17 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Bausch Health Companies logo
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
Read More

Today's Range

Now: $7.47
Low: $7.33
High: $7.59

50 Day Range

MA: $8.33
Low: $7.34
High: $9.78

52 Week Range

Now: $7.47
Low: $3.96
High: $11.46

Volume

1,232,922 shs

Average Volume

2,748,763 shs

Market Capitalization

$2.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of Bausch Health Companies?

The following Wall Street analysts have issued research reports on Bausch Health Companies in the last year: Evercore ISI, Jefferies Financial Group Inc., Piper Sandler, Raymond James, Royal Bank of Canada, Scotiabank, StockNews.com, and Truist Financial Co..
View the latest analyst ratings for BHC.

What is the current price target for Bausch Health Companies?

0 Wall Street analysts have set twelve-month price targets for Bausch Health Companies in the last year. Their average twelve-month price target is $7.75, suggesting a possible upside of 3.7%. Royal Bank of Canada has the highest price target set, predicting BHC will reach $11.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $3.00 for Bausch Health Companies in the next year.
View the latest price targets for BHC.

What is the current consensus analyst rating for Bausch Health Companies?

Bausch Health Companies currently has 1 sell rating, 5 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in BHC, but not buy more shares or sell existing shares.
View the latest ratings for BHC.

What other companies compete with Bausch Health Companies?

Other companies that are similar to Bausch Health Companies include Qiagen, Intra-Cellular Therapies, Roivant Sciences, Ascendis Pharma A/S and Revolution Medicines. Learn More about companies similar to Bausch Health Companies.

How do I contact Bausch Health Companies' investor relations team?

Bausch Health Companies' physical mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The company's listed phone number is (514) 744-6792 and its investor relations email address is [email protected]. The official website for Bausch Health Companies is www.bauschhealth.com. Learn More about contacing Bausch Health Companies investor relations.